Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It’s an AB-rated generic therapeutic version of Durezol
A treatment to prevent extreme symptoms and cut hospitalisation
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
